n Greek mythology, a chimaera is a fearsome fire-breathing beast composed of different parts of more than one animal, vividly depicted in Homer's Iliad as a lion-headed creature with the body of a goat and the tail of a serpent. In modern bioscience, chimaeras are entities made up of cells from different organisms. They are extremely valuable basic biology research tools with the potential for future clinical use. Experimental chimaeras generated from cells of more than one individual of the same species, particularly the mouse, have been widely used for many biomedical studies. Here, however, we focus on mammalian chimaeras generated from different species, also known as interspecies chimaeras (see Box 1 for related terminologies), which have recently garnered attention among researchers and the public, owing to their potential for providing replacement human organs. This Review will first provide a historical perspective and a summary of recent advances in stem-cell-derived interspecies chimaeras and their potential applications. It will go on to discuss ethical guidelines, current policies, societal effects and, finally, conclude with an outlook on research in this and related areas. Interspecies chimaera-related research covers a broad range of topics. We focus here on studies that deliver donor stem cells to pre-natal host embryos and fetuses-research on conventional xenotransplantation approaches involving the introduction of donor cells into the post-natal animal has been reviewed elsewhere 1 .
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Earlier studies on interspecies chimaeras
Interspecies chimaeras in mammals were first developed in the 1970s as tools to aid the study of cell lineage and cell fate during embryonic development. Prior to the development of transgenic reporter lines, there was a need to explore other ways of identifying the origin of the different cell types brought together in a chimaera. Building on the pioneering work of Le Douarin and colleagues using chick-quail chimaeras 2, 3 , in the 1970s Gardner and Johnson were the first to test the species boundaries in mammals with rat-mouse chimaeras 4 . When rat inner cell masses (ICMs) were injected into mouse blastocysts and transferred to the mouse uterus, the detailed distribution of the rat-derived cells could be observed in sections of the fetuses using species-specific antibodies. However, when the chimaeras were left to go to term, the resulting offspring had very few detectable rat cells remaining. The reason for this loss is still not clear, but it was suggested that different developmental rates between two species, that diverged evolutionarily about 20.9 million years ago (www.timetree. org), could lead to selection against the rat cells.
Interspecies chimaeras between two more closely related murine species, Mus musculus and Mus caroli, were generated in further work by Rossart and Frels 5 . Live chimaeras with cell contributions from both species were produced by injection of M. caroli ICMs into M. musculus blastocysts 5 . DNA-DNA in situ hybridization and differences in satellite DNA between the two species were used to provide a detailed description of the tissue types derived from the ICM and the trophectoderm of the blastocyst 6 . Following this success, other viable interspecies chimaeras were also generated, including sheep-goat 7 and two bovine species, Bos taurus-Bos indicus 8 . The successful production of interspecies chimaeras is dependent on the matching of the species origin of the trophectoderm derivatives and that of the maternal uterus. Mus caroli blastocysts, for example, cannot survive beyond early postimplantation in the uterus of M. musculus; however, viable M. caroli offspring can be produced from a M. musculus mother when a blastocyst is reconstituted with M. musculus trophectoderm and M. caroli ICM 9, 10 . This suggests that species boundaries can be extended considerably, provided that the interspecies combination is confined to the ICM derivatives.
These early studies paved the way for understanding evolutionarily conserved and divergent developmental processes in an interspecies setting in vivo. The derivation of pluripotent stem (PS) cells from early embryos, as well as from differentiated cells through cellular reprogramming, has renewed the interest in generating interspecies chimaeras 11 .
Stem cells and interspecies chimaeras
The first PS-cell-derived interspecies chimaeras were generated by Lahn and colleagues by injecting embryonic stem (ES) cells of the wood mouse Apodemus sylvaticus into M. musculus blastocysts. Although A. sylvaticus diverged from M. musculus about 14.59 million years ago, viable chimaeras were obtained that contained a considerable contribution (up to 40% in some tissues) of A. sylvaticus cells in all major organs, including germ cells, in mice 12 . Notably, A. sylvaticus-M. musculus chimaeras displayed features that were intermediate between the two species, including eye size and jumpiness, although these phenotypes were not statistically quantified 12 . Whether or not interspecies chimaeras can retain behavioural traits characteristic of the donor species is an intriguing question. A recent study by Goldman and colleagues has suggested that the extensive contribution of human glial progenitors after grafting into the post-natal mouse forebrain could alter the cognitive capability of the host 13 . Improvement in mouse ES cell culture eventually enabled the derivation of germline-competent rat ES cells [14] [15] [16] , rekindling the interest in generating rat-mouse chimaeras. A milestone study by Nakauchi and colleagues reported the generation of viable adult rat-mouse chimaeras Chimaeras are both monsters of the ancient imagination and a long-established research tool. Recent advances, particularly those dealing with the identification and generation of various kinds of stem cells, have broadened the repertoire and utility of mammalian interspecies chimaeras and carved out new paths towards understanding fundamental biology as well as potential clinical applications.
by the injection of rat PS cells into mouse blastocysts or by injection of mouse PS cells into rat blastocysts 17 . Chimaerism in interspecies fetuses varied among individuals and tissues, but was lower than that in the mouse-mouse or rat-rat intraspecies chimaeras. The production of viable rat PS-cell-derived rat-mouse chimaeras has been confirmed by other studies (ref. 18 and J.W. et al., manuscript in preparation). Wu et al. further showed that rat PS-cell-derived rat-mouse chimaera aged normally and lived an entire mouse life span (about 2 years) (J.W. et al., manuscript in preparation). The higher chimaerism rate of rat PS cells versus rat ICMs suggest that rat PS cells may have growth advantages over rat ICMs, perhaps as a result of their in vitro culture. The phenotype of rat-mouse chimaeras provides several insights. First, the chimaeras born from rat surrogates were generally rat-sized and those born from mouse surrogates were mouse-sized unless there were high contributions by the xenogenic PS cells, a factor which was typically associated with morphological abnormalities and embryonic lethality 17 . Second, the chimaeric contribution of xenogenic cells seems to display lineage bias. Although a high percentage of mouse CD45 + cells were detected in rat-blastocyst-derived chimaeric livers, rat CD45 + blood cells were rarely detected in mouse-blastocyst-derived chimaeric fetal livers 17 . This observation was specific to interspecies chimaeras, as the same rat PS cell line efficiently contributed to CD45 + cells in intraspecies chimaeric fetal livers 17 . Third, as mice have a gallbladder whereas rats do not, the presence or absence of the gallbladder in rat-mouse chimaeras appeared to be determined by the host species, suggesting that the donor PS cell derivatives are subject to regulation by the host programs that drive organogenesis 17 . Intriguingly, Wu et al. recently found rat PS cells could contribute to mouse gallbladder, suggesting that the mouse embryonic microenvironment was able to unlock a gallbladder developmental program in rat cells that is normally suppressed during rat development (J.W. et al., manuscript in preparation). Whether or not high contributions of rat PS cells to mouse-blastocyst-derived chimaeras would interfere with mouse gallbladder development remains an interesting, unresolved issue.
Unlike rodents, germline-competent ES cells have yet to be isolated from other species. Stable ES cell lines could be derived from both nonhuman primate and human blastocysts [19] [20] [21] [22] [23] [24] ; however, not one of these lines was able to generate intra-or interspecies blastocyst chimaeras [25] [26] [27] . It was later realized that the rodent and primate ES cells represent different phases of pluripotency, naive and primed, respectively 28 . Mouse ES cells represent the naive epiblast state 29 , whereas epiblast stem cells (EpiS cells), another PS cell type derived from the post-implantation epiblast of rodent embryos 30, 31 , are primed for differentiation. Many defining features of EpiS cells were frequently found in primate ES cells, suggesting that primate ES cells were stabilized at the primed pluripotent state. Consistent with their post-implantation identity, mouse EpiS cells can engraft into egg cylinders in culture and differentiate into all three embryonic germ lineages, including primordial germ cells [32] [33] [34] . Similarly, human PS cells grown in different primed cultures can also integrate into mouse gastrula-stage embryos and form ex vivo interspecies chimaeras 34, 35 . Izpisua Belmonte and colleagues have since shown that primed human PS cells could chimaerize gastrula stage chick embryos as well (J.W. et al., unpublished data). Thus, gastrula-stage embryos, rather than pre-implantation blastocysts, permit primed human PS cells to engraft and cross the xenobarrier 36, 37 . With the recognition that primate ES cells correspond to the primed state, an unresolved question was whether human PS cells that were more similar to mouse ES cells could be obtained. Derivation of genuine naive human ES cells, if achieved, would provide several practical advantages over primed cells, including improved single-cell cloning efficiency, ease of genome editing and the potential to generate interspecies chimaeras. The first successful attempt at generating mouse-ES-cell-like human ES cells came from a study by Jaenisch and colleagues in which the forced expression of Oct4 (also known as Pou5f1), Klf4 and Klf2 transcription factors was used to revert primed human ES cells to a more immature state. Although converted cells share many salient features of mouse ES cells, their long-term maintenance was still dependent on ectopic transgene expression 38 . Following this pioneering work, a flurry of recent studies have reported conditions that produce stable, transgene-free immature human PS cells with molecular features resembling mouse ES cells [39] [40] [41] [42] [43] [44] [45] [46] [47] . Some of these cultures have also been used for the de novo derivation of human ES cells from human blastocysts 41, 43, 46, 47 . It has proven difficult to define the gold standard criteria for assigning the true naive human pluripotent state 48 . Fan and colleagues used a systems biology approach to assess the gene networks of different PS cells and found that the gene networks of mouse ES cells and EpiS cells were reproducible across all datasets examined; however, naive human PS cells grown in different cultures exhibited high degrees of variation 49 . Naive gene networks appeared to be poorly conserved between human and mouse PS cells, and both better resembled their respective blastocysts 49 . Thus, a direct comparison of naive human PS cells to pre-implantation human embryos can potentially serve as a more reliable molecular criterion for defining the human naive pluripotent state. In this regard, a recent study showed that the gene expression profiles of naive 5i-and T2iLGö-conditioned human PS cells better correspond to that of the human cleavage-stage embryo than cells produced by other protocols 44 .
Validation of the naive state pluripotency in the mouse is achieved by demonstrating the functional contributions made by the mouse PS cells to blastocyst chimaeras. Owing to ethical considerations, the testing of human putative naive cells in such assays is limited to the use of animal host embryos, usually the mouse. Initial attempts at generating humanmouse chimaeric embryos using naive human PS cells highlight the potential difficulties that lie ahead in establishing interspecies chimaeric
Box 1 defining chimaeras
A chimaera is typically defined as an organism composed of a mixture of different cell populations that derive from more than one zygote. They can be formed by processes such as the mixing of early embryos or the grafting of tissues from different stages of development or the adult. Chimaeras are distinct from hybrids (offspring resulting from breeding between different species) and from mosaics (animals carrying genetically different cells that originated from the same zygote). Chimaeras can be categorized as intraspecies or interspecies, depending on whether cell derivatives from two zygotes are from the same or different species, respectively.
Creating interspecies chimaeras requires a donor species and a host species. The donor species provides cells of embryonic, fetal, or adult origin, either from primary tissue or from cell cultures. The host species provides the physiological environment and life support for embryonic, fetal, or adult chimaeric animals. In stem-cell research, the generation of an interspecies chimaera often involves the transplantation of multi-or pluripotent stem (PS) cells from the donor into an animal recipient at embryonic, fetal or post-natal stages of development.
Tissue distribution and duration of chimaerism often differ depending on the donor cell type and the developmental stage of the host. PS cells are less restricted in developmental potential than other stem-cell types and thus can give rise to a high degree of chimaerism with wide tissue distribution when transferred to pre-implantation host embryos. Chimaeras generated by progenitors or adult stem cells are more confined to specific tissues and may need to be grafted to appropriate sites and developmental stages. Chimaeras are often designated according to the developmental age of the host at the time of analysis (for example, chimaeric embryos and chimaeric fetuses) or at the time of donor cell injection (for example, blastocyst chimaeras).
Other important distinctions are between heterotopic and orthotopic, and heterochronic and isochronic chimaeras. Orthotopic chimaeras are generated by transplanting donor cells to their cognate location where they can participate in natural developmental processes or proper tissue organization of the host (for example, transplanting donor hepatocytes to the host liver). Heterotopic chimaeras occur with differentiation or integration of donor cells at a different site within the host animal than their origin (for example, transplanting donor pancreatic β -cells to the host liver). Heterochronic and isochronic chimaeras are distinguished by the temporal properties between donor and host. If donor cells are delivered to the host at a time matching their in vivo origin, an isochronic chimaera will be formed, otherwise the chimaera formed will be heterochronic. models. Hanna and colleagues reported the robust generation of embryonic day (E)10.5 human-mouse chimaeric embryos using human PS cells grown in NHSM medium 41 . By contrast, there were several other studies that contradicted this conclusion, outlining the inefficient, limited chimaeric contribution of cells cultured in NHSM medium or other naive conditions [42] [43] [44] 50 . Notably, though, non-human primate PS cells cultured in modified NHSM cultures were reported to contribute to the formation of pre-natal monkey-monkey and monkey-mouse chimaeras, albeit to a modest degree 51, 52 . In most studies, the criteria used to evaluate chimaerism were exclusively based on the presence of fluorescently labelled human cells. There are several potential problems associated with this, especially when the degree of chimaerism is low, including auto-fluorescence and the uptake of markers from dying cells. A recent study, by Theunissen et al. 44 used both fluorescence detection and quantitative PCR analysis of human mitochondrial DNA (sensitive enough to detect a single human cell in 10,000 mouse cells), to analyse 1,400 putative human-mouse chimaeric embryos, finding only 7 to be truly chimaeric 44 . Those that were chimaeras contained between 1 and 4 human cells per 10,000 mouse cells. Although the absence of human mitochondrial DNA is a strong negative result, the presence of a positive signal does not necessarily indicate the functional integration of donor cells as DNA can be derived from dead cells or contamination during sample preparations. Similarly, the presence of GFP-positive donor cells alone is not definitive proof for chimaeric contribution as human PS-cell-derived cells often appear as a cluster and do not fully integrate into animal tissues. Definitive proof of human-animal chimaera formation therefore requires evidence of functional contributions.
Review ReSeARCH
Humans and mice differ considerably in various aspects, including post-implantation epiblast development, embryo size, speed of development and gestational period. These and other differences may affect the integration, proliferation and differentiation of human PS cells in the chimaeric epiblast. Interspecies chimaera research with large animal hosts that are more similar to humans in anatomy, physiology and organ size could result in an improved research model. Experiments evaluating the chimaeric contribution of various human PS cells in large animal hosts are currently lacking. Izpisua Belmonte and colleagues have injected several existing human PS cell lines into pig blastocysts followed by embryo transfer to surrogate sows and results seem to agree with those from human-mouse chimaeric studies (J.W. et al., manuscript in preparation). Interestingly, both rat and mouse PS cells, which can robustly generate interspecies chimaeras among rodents, failed in chimaeric contribution to day E21-E28 pig embryos (J.W. et al., manuscript in preparation). Parallel attempts by Nakauchi and colleagues to inject human PS cells into sheep morulae/blastocysts have found a similarly limited human chimaeric contribution 28 days after transfer into surrogate ewes (T. Rashid et al., unpublished data) .
In addition to PS cells, more developmentally restricted stem/ progenitor cells are also amenable to chimaera formation. Neural crest cells (NCCs), a multipotent embryonic progenitor cell population, first emerge in the neural plate border region, between the neural epithelium and epidermis during neurulation 53 . Jaenisch and colleagues injected NCCs derived from E8.5 mouse embryos, as well as those from mouse ES cells, into the amniotic cavity of E8.5 mouse embryos in utero 54, 55 . This allowed the NCCs to enter the neural tube through the open neuropore, thereby contributing to chimaeric pigmentation formation in post-natal mice 54, 55 . More recently, the authors also generated interspecies neural crest chimaeras after transplanting PS-cell-derived rat and human NCCs into E8.5 mouse embryos in utero. Notably, both the rat-mouse and human-mouse neural crest chimaeras were born and the donor cells differentiated and matured into functional melanocytes and contributed to visible hair pigmentation in the adult mouse 56 . Human neural stem cells have also been transplanted into rat fetuses to generate interspecies chimaeric brains 57, 58 . Transplanted human neural stem cells displayed wide chimaeric contribution to the rat central nervous system and gave rise to neurons, astrocytes and oligodendrocytes. Human haematopoietic stem cells (HSCs) have been routinely transplanted into immunodeficient mice to assess their function and differentiation capacity 59 ; however, this is mostly by post-natal injection. Human-sheep and human-pig haematopoietic chimaeras, generated via the in utero transplantation of human CD34 + haematopoietic stem progenitor cells, have been reported but the contribution of human blood cells was limited in these experiments-probably because host HSCs competed with transplanted cells for the stem-cell niche 60, 61 . A summary of chimaeras generated using different types of cultured stem cells is provided in Fig. 1 .
Factors involved in interspecies chimaerism
To improve the degree of chimaerism achieved from the transplantation of xenogeneic stem cells, especially PS cells, several important factors need to be considered (Fig. 2) .
Matched developmental timing
Transplantation of donor cells into developmental-stage-matched (isochronic) host tissue may be critical for the efficient engraftment of cells into chimaeras. Mouse ES cells were able to gain entry into host development following blastocyst injection but failed to thrive in the post-implantation epiblast 32 . Conversely, although mouse EpiS cells are inefficient at generating blastocyst chimaeras, they are capable of colonizing the E7.5, but not the E8. 27, 34, 35 , pig and cow (J.W. et al., manuscript in preparation) blastocysts. Several studies reported heterochronic chimaeras, in which cells of early developmental ages were able to respond to a later tissue environment. Gage and colleagues 62 injected human ES cells into the lateral ventricle of E14 mice. The E14 mouse brain allowed some injected human ES cells to differentiate and generate mature, active human neurons in the adult mouse forebrain, unlike the post-natal brain, in which human ES cells generate teratomas 62 . Shinohara and colleagues generated functional spermatozoa after transplantation of E6.5 epiblast or E8.5-E16.5 mouse fetal germ cells into the seminiferous tubules of a post-natal mouse testis 63 . The reverse experiments, in which more advanced cells were returned to earlier-stage embryos, were less successful. Primordial germ cells isolated from post-implantation E8.5-E11.5 embryos did not contribute to chimaera formation following blastocyst injection 64 . Several groups have reported the transplantation of various differentiated lineagessuch as neural precursor cells, HSCs or mesenchymal stem cells-into blastocysts and have claimed that the injected cells contributed to the respective lineages [65] [66] [67] [68] . The validity of these findings has, however, not been confirmed and remains controversial.
Providing selective advantage for donor cells
Several strategies may confer a selective growth advantage to donor cells. First, an empty host niche strategy. If the host is genetically modified, compromising or eliminating the development of certain cell lineage(s) in embryogenesis, the recipient niche can be used exclusively by donor cells for their differentiation, proliferation and function. This strategy has been widely used for assaying HSC functions in vivo after the myeloablative irradiation of a donor's bone-marrow stem-cell niche 69 . Spermatogonial stem cells or primordial germ cells can be injected into the seminiferous tubules of a recipient W/W V mouse testis lacking endogenous germ cells for proper spermatogenesis 63, 70, 71 . c-Kit-mutant W sh /W sh mice that lack melanoblasts are more permissive for the chimaeric contribution of NCCs derived from rodent and human PS cells 56 . Notably, this concept has also been adapted for the generation of xenogenic organs via interspecies blastocyst complementation (refs 17, 18 and J.W. et al., manuscript in preparation).
Second, a cell-competition strategy. Cell competition was first studied in Drosophila in which cells carrying a Minute (also known as RpS17) mutation were outcompeted by wild-type cells with metabolic advantages 72 . Later studies in mammalian systems revealed that this process is universal and highly conserved 73 . MYC-induced supercompetition constitutes another mode of cell competition, in which cells with higher MYC expression out-compete neighbouring wildtype cells 73 . Both types of cell competition have, thus far, only been examined in the intraspecies setting and their roles in interspecies chimaera formation await exploration. Overexpression of c-MYC in human-PS-cell-derived NCCs did not seem to give a more competitive edge for human cells, suggesting that super-competition conferred by c-MYC may not work across species 56 . Zwaka and colleagues identified a network of genes whose downregulation confers embryonic cells with the ability to out-compete wild-type cells in development, a feature reminiscent of MYC-driven super-competition 74 . Whether or not expression of these pro-competition genes would promote cross-species contributions remains to be determined.
Third, an enhancement of donor cell survival approach. Nakauchi and colleagues found cells from a subclone of EpiS cells could generate blastocyst chimaeras, in part owing to their resistance to cell death after injection into blastocysts 50 . This led to further examination of whether the forced expression of the anti-apoptotic protein BCL2 might allow primed PS cells to engraft in blastocysts, survive and contribute to chimaeras. Indeed, BCL2-overexpressing EpiS cells also survived in mouse blastocysts and contributed to chimaeric mice 75 . Furthermore, when BCL2-expressing SOX17 + endoderm progenitors were injected into blastocysts, they also contributed to chimaera formation, but only to gut tissues 75 . These results suggest that the prevention of apoptosis supports the survival of grafted progenitors in pre-implantation embryos and can extend the degree of heterochrony that can be tolerated in blastocyst chimaeras. Once the appropriate differentiation stage is reached, surviving progenitors will then take part in embryogenesis and follow their ordained developmental fate. The prevention of apoptosis is also a valid strategy for mouse-rat interspecies chimaera formation. For example, BCL2-expressing rat primed PS cells can contribute to chimaeras after injection into mouse blastocysts 75 . BCL2 overexpression also promoted human ES cell survival in mouse embryos
in vitro (H. Masaki et al., unpublished data). Similar results were obtained with BCL2-overexpressing monkey ES cell lines in mouse embryos in vivo (H. Masaki et al., unpublished data)
. Although the data are promising, it should be noted that the progeny of primate PS-cellderived cells were diverted towards the extraembryonic lineage. Thus, more experiments and optimizations are warranted before any definitive conclusions can be drawn.
Evolutionary considerations
Overall, the generation of interspecies chimaeras between mouse and rat is less efficient than the generation of intraspecies chimaeras. The cause of this 'xenobarrier' is not clear; however, there are several potential reasons, including ligand-receptor incompatibilities and differences in the affinity of adhesion molecules as a result of genetic diversification. To gain evolutionary insights into the xenobarrier, Nakauchi and colleagues generated induced pluripotent stem (iPS) cells from the prairie vole (Microtus ochrogaster), a rodent species that diverged from M. musculus about 32.7 million years ago. When prairie vole iPS cells were injected into mouse embryos, interspecies chimaeras could be generated, but the embryonic development rate, degree of chimaerism and survival to adulthood were lower than in mouse-rat chimaeras (H. Sato et al., manuscript in preparation). These data imply that genetic diversification or evolutionary distance is at least partly responsible for the xenobarrier. In line with this, Jaenisch and colleagues observed a greater chimaeric contribution of mouse NCCs to the mouse embryo than that made by rat NCCs, and rat NCCs showed more efficient engraftment than human NCCs 56 .
Potential applications
Interspecies chimaeras are excellent experimental models for studying development, organismal homeostasis, stem-cell potential and disease. Recently, progress in several technological frontiers has opened new possibilities for interspecies chimaera research. Through genetic manipulation, the developmental niche(s) of the host animal can be made to serve donor cells exclusively, thereby generating organ-or tissue-enriched chimaeras, which at some stage could help provide much-needed organs for transplant. Interspecies chimaeras with human stem-cell contributions could also serve as a platform for disease modelling and drug screening, providing in vivo readouts of disease onset and progression, drug efficacy and toxicity, with relevant clinical value 11 (Fig. 3) .
Organ generation
This can be potentially approached with blastocyst complementation or targeted organ complementation.
Interspecies blastocyst complementation. The ability to grow entire body parts for patients in the laboratory, as replacements for damaged or failing organs, is the holy grail of regenerative medicine. This quest took a considerable step forwards ten years ago with the discovery of iPS cells 76 . Although efforts have been made to generate functional mature cells from iPS cells that target diseases that are potentially amenable to treatment by cell transplantation, other conditions, such as heart, kidney, liver and lung failure, require whole-organ replacement. Generating such complex, three-dimensional tissues from iPS cells once seemed impossible. In 2010, Nakauchi and colleagues reported the generation of a rat pancreas in mouse, using rat iPS cells to complement the pancreatic organ niche in mouse embryos that are unable to develop a pancreas 17 . More recently, the same group succeeded in generating a mouse pancreas in Pdx1 −/− rats (T. Yamaguchi et al., manuscript in preparation). To evaluate functionality, mouse islets formed in rats were transplanted into mice with streptozotocininduced diabetes. Although the isolated islets contained some rat endothelial cells and other non-parenchymal cells, 100 islets transplanted under the mouse renal capsule normalized blood glucose levels over 370 days without immunosuppression (T. Yamaguchi et al., manuscript in preparation). This proof-of-concept study indicates that organs generated from iPS cells in this manner can be just as functional as those from wild-type animals. In addition to pancreas, Isotani et al. 18 complemented blastocysts from nude mice lacking a thymus with rat ES cells and generated an xenogenic rat thymus. Usui et al. tested the blastocyst complementation strategy for the generation of kidney tissue in Sall1-knockout mice. When mouse PS cells were used, a kidney was successfully generated. However, rat PS cells failed in this context, suggesting that key molecules involved in the interaction between mesenchyme and ureteric bud during kidney development might not be conserved between mice and rats 77 . Most recently, Izpisua Belmonte and colleagues broadened the utility of interspecies blastocyst complementation by combining CRISPR-Cas9-mediated zygote genome editing with the blastocyst injection of rat PS cells, thereby removing the need for existing mutant mouse strains (J.W. et al., manuscript in preparation). This strategy allowed successful complementation for several lineages, including pancreas, heart and the eye, among others (J.W. et al., manuscript in preparation).
These proof-of-concept studies could perhaps be expanded beyond rodents to larger animals, whose organs are much more similar in size to those of humans. That is, pig, sheep or monkey embryos may eventually be complemented with human stem cells to generate replacement organs for any part of the human body. Pig-pig blastocyst complementation has already been achieved by Nakauchi and colleagues 78 . Pig fibroblasts overexpressing the transcriptional repressor HES1 under the pancreasspecific PDX1 promoter were cloned to give rise to embryos carrying a PDX1-HES1 transgene 78 . PDX1-HES1 expression suppresses the pancreatic development program, thus leading to the creation of pancreatogenesis-disabled pig embryos. Owing to the lack of chimaeracompetent pig PS cells, cloned blastomeres expressing the fluorescent protein huKO were used to complement the PDX1-HES1 embryos. These huKO + blastomeres were able to contribute to chimaera formation, generating an entire huKO + pancreatic epithelium. Moreover, the chimaeric pigs generated by complementation were able to grow into adulthood with a functional pancreas. Whether or not human PS cells can generate xenogeneic organs in pigs remains unknown. Although similar in physiology and organ size, the evolutionary distance between human and pig (96 million years) is even greater than that between human and mouse (90 million years). Thus, the chimaeric contribution made by human PS cells is expected to be low in pigs, consistent with recent findings (J.W. et al, manuscript in preparation). Choosing a species closer to humans, such as non-human primates, may be more likely to work, although the law in many countries prohibits such experiments. Developing strategies to improve human chimaerism in a distant animal host as discussed above, could help to turn this goal into reality in the future. Interspecies targeted organ complementation. One of the issues regarding in vivo organ generation in animals is ethical concern over potential gamete and neural contribution from PS cells. This issue could be addressed by developing methods of targeted organ generation, minimizing the likelihood of any undesired gameto-or neurogenesis 79 . One approach is to modify PS cells, restricting their differentiation to the organ of interest. Conditional expression of the transcription factor gene Mixl1 made it possible to induce differentiation of PS-cell-derived cells towards the endodermal lineage, thereby reducing the number of non-endodermal PS-cell-derived cells 80 . The introduction of constructs containing suicide genes under neural-or germ-cell-specific promoters to eliminate completely the formation of human iPS-cell-derived neural and germ cells in the host animal could be explored. Another approach is the use of committed progenitors or organ buds instead of PS cells. As discussed, the organ niche of organ-deficient embryos is available for complementation throughout development of the organ. Therefore, injecting lineagecommitted progenitor cells, (such as cultured nephron progenitor cells 81 , rather than PS cells, into the embryo at the right place and time may allow complementation of organ deficiency with little chance of generating 'off-target' humanized tissues.
If the host organ niche is emptied by genetic manipulations, donor human progenitor cells will probably be able to colonize it, giving rise to a human-cell-enriched organ. Although theoretically this is a sound strategy and potentially reduces the ethical concern, there are caveats: the developmental stages need to be matched between human progenitors and the host animal fetus; delivering human cells before the host organ becomes atretic is likely to be critical and challenging; and delivery of human progenitor cells needs to be performed before the host immune system is formed (less than 50 days in pigs).
In vivo disease modelling
An important goal of experimental biology is the development of model systems that allow for the study of human diseases under in vivo conditions. Transgenic animals have been successful in modelling a variety of human diseases but have failed to provide disease-appropriate phenotypes for monogenic diseases such as Lesch-Nyhan syndrome 82 or of complex diseases such as Parkinson's or Alzheimer's. Given that disease-specific iPS cells carry all genetic alterations that contributed to disease pathology, the functional integration of patient-derived cells into the tissues of the developing mouse embryo would allow for study of the initiation, progression and manifestation of the disease in question. Host-specific developmental and physiological programs may alter the behaviour of donor human cells in a non-human host. Nevertheless, the ability to study the autonomous versus non-autonomous effects of the multiple genetic alterations that contribute to a human disease under in vivo conditions cannot be dismissed.
In vivo drug screening
Compared to existing drug screening platforms, which often involve the use of patient samples and immortalized cell lines and/or in vivo transgenic mouse models, the use of interspecies chimaeras with human stem cells could potentially offer a superior in vivo drug-screening platform. Interspecies chimaeric formation using human iPS cells or iPS-cellderived progenitors offers an attractive platform for the personalized in vivo testing for drug efficacy and toxicity. This approach holds the potential to be a robust preclinical testing platform for more accurate predictions of clinical outcomes.
Ethical, legal and social issues
In his January 2006 State of the Union address, President George W. Bush asked Congress to pass the 'Human Chimaera Prohibition Act' that would have made many activities that involve the mixing of human genes, cells, or tissues with those of non-human animals illegal 83 . Ten years later, political, ethical, and social concerns about chimaeras remain.
The issues
Four major ethical and social issues exist concerning research with, and potential human clinical use of, chimaeras: animal welfare, sources of donor cells, general public discomfort with chimaeras, and the 'humanization' of the host species.
With chimaeras, as with any new intervention with non-human animals, the pain or disability the animals could suffer may be hard to predict. Researchers must therefore be more sensitive to the possibility of pain and suffering than with existing, well-characterized laboratory animals 84, 85 . If chimaeras were ultimately developed to provide transplants for humans, carnivorous societies should not ban their use, but their humane treatment and slaughter would be essential.
Although widely legal for research use, some people consider the use of human ES cells or of cells derived from aborted fetuses unethical; this would be true for chimaeras as well.
Public discomfort, sometimes expressed as concerns about 'unnaturalness' , clearly exists around chimaeras. These seem to boil down to a belief that any species mixing is inherently wrong 86 . Whether public concerns without a good logical basis 87 should be considered 'ethical' issues is debatable, but this could have a considerable effect on research and its funding.
The most controversial aspect of human-non-human chimaeras has been the fear that they may in some way confer ethically important human characteristics on non-human hosts. Substantial discussion of the humanization concern started around 2003 (ref. 88 ) and has continued for several years 84, 85, [89] [90] [91] . The precise concerns about humanization have 
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Figure 3 | Potential application of interspecies chimaeras with human stem cells. Organ generation via interspecies blastocyst complementation or interspecies targeted organ complementation could help to solve the severe shortage of organ donors worldwide. Human-animal chimaeras will also help researchers to understand the aetiology, onset and progression of human diseases better. Additionally, they could be useful for testing the efficacy and safety of a candidate drug in vivo.
remained unclear. One author argues that three specific characteristics of human-non-human chimaeras should be carefully examined: human-like cognitive abilities, human gametes, or human-like appearances 92 . Most discussion has focused on the brain; some suggest that chimaeras could lead to moral confusion of humans and non-humans 88 or diminution of human dignity 89, 90, 93, 94 . One powerful, albeit unlikely, concern is that such chimaeras could achieve sufficient human-like consciousness or intelligence to 'deserve' , but be denied, personhood 91 . Others merely note that the issue is controversial and argue that researchers should be very careful with research that could be seen as possibly giving the host some humanlike cognitive abilities 84, 85 . As parts of this Review have indicated, the creation of a non-human animal with a substantially human brain, or with enough human characteristics to warrant human treatment 95 seems, at present, unlikelyespecially given the possible measures to limit unplanned spread of the stem cells. The possibility cannot be entirely dismissed; one study has already shown improvements in mouse memory after insertion of human glial progenitor cells 13 and the increasing use of naive human PS cells may lead to wider differentiation.
Laws, regulations and guidance
Different national laws and regulations concerning laboratory animal care and use exist, as they do for proper treatment of animals reared for food. These need only to be carefully applied to novel chimaeric animals. Similarly, varying national laws and regulations govern the use of fetal tissue or human ES cells in research. Because chimaera research might produce dramatic results, public attention could easily be brought to these issues. The following case, concerning the United States, may indicate how some these concerns may be handled.
In the late 1980s, the United States banned the federal funding of research with fetal tissue 95 . The 1993 NIH Revitalization Act 96 authorized federal funding for research involving appropriately obtained fetal tissue. Recent controversy over Planned Parenthood's acquisition of fetal tissue for transfer to researchers has revived controversy about this statute.
Similarly, federal funding for research that could create human ES cells has been banned since 1995. In 2000, the Clinton administration concluded that this allowed federal funding of research to study human ES cell lines that others had created using non-federal funding. The Bush administration stringently limited the extent of such funding, although the Obama administration broadly permitted it in 2009-a position that was upheld by a federal appellate court 97 . The position, however, can be changed by legislation or by a policy decision introduced by a new president. (Note that, in the United States, this issue has mainly concerned federal funding for research, not limitation of non-federally funded research.)
Of the ethical concerns surrounding the generation of chimaeras, humanization has received the most attention, largely through guidance rather than law or regulation. Human-non-human chimaera research has been addressed as part of general guidelines from the following bod- . The guidelines urge that the insertion of human stem cells (or tissues) into non-human animals be reviewed by oversight committees. Under the NAS guidelines, when a committee reviews a protocol, "particular attention should be paid to the probable pattern and effects of differentiation and integration of the human cells into the non-human animal tissues". The NAS guidelines also ensure that the animals that have received human cells or tissues are not allowed to breed, for fear that they may produce human gametes 103 . These guidelines also contain some useful specific prohibitions, such as those on placing any ES cells in human blastocysts or human ES cells into the blastocysts of non-human primates.
If properly applied, these guidelines should help to assuage concerns regarding humanization. After considering the likely patterns of differentiation and distribution, the overseeing committees should not approve research that has a considerable chance of potentially conferring human cognitive characteristics onto chimaeras or creating a human appearance.
No regulations or guidelines directly address unspecified public concerns about chimaeras. One group urged that researchers react to these worries by being open and transparent about their research, while regularly making the case that such research is important 84 . The real consequences of ethical and social concerns about chimaeras are not ancient history. In September 2015 the US NIH announced a moratorium on funding any research in which human pluripotent cells or human neural progenitor cells were placed into any non-human vertebrate embryo before gastrulation 104 ; however, the reasons for this were unclear. In November 2015, the NIH held a workshop to discuss these issues and, in August 2016, issued a draft policy calling for an internal NIH committee to review applications for some types of human-non-human chimaera funding 105, 106 . The recent US presidential election adds considerably uncertainty to the future of this line of research.
Conclusion and outlook
Notwithstanding any ground-breaking advances in generating animal interspecies chimaeras, there are currently more questions than answers concerning human-non-human chimaeras. It is not known whether more extensive chimaerism can be obtained between humans and other more related species, nor is it known whether human organs generated in chimaeras, with host nerves and vasculature, will be suitable for transplantation. In this regard, strategies such as the humanization of host animals and/or multi-lineage complementation may help. Fundamental problems remain, such as how best to resolve heterochronic developmental processes and inherent differences in gestation length between humans and other species; whether or not xeno-generated human cells, tissues and organs would be functionally compatible with human physiology; and whether it is possible to generate human cells that are able to compete equally with host cells.
The development of strategies to enhance the degree of humananimal chimaerism, such as those described in this Review, will be necessary if interspecies chimaeras are to reach their full biological and clinical potential. Engineering approaches to confer human stem cells with novel genetic circuits that monitor and control specific cell behaviours may help to overcome some of the present human-animal interspecies barriers. Similarly, engineering approaches to humanize animal models may help to lower the threshold of xenotransplantation. If successful, these new approaches, rooted in the fields of cell and developmental biology, may expand the breadth of chimaera research from the laboratory into potential clinical applications. This could aid the development of new drug screening, efficacy and toxicity methodologies, as well as the creation of disease models that may ultimately enhance diagnosis and improve the treatment of numerous pathologies.
Although the way ahead has many scientific, medical, ethical, political, financial, and other challenges and not everything that can be done in the field of chimaera research should be done, we owe it to future generations of patients and scientists to think about these challenges and experimentally proceed forward with consensual ethical, legal and social guidelines.
